跳至主要内容
临床试验/JPRN-UMIN000038296
JPRN-UMIN000038296已完成未知

Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917) - Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917)

Kinki Breast Cancer Study Group0 个研究点目标入组 128 人开始时间: 2019年10月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Has received any investigational new drug or any approved drug without breast cancer indication in any clinical trial as the following therapy after T-DM1 treatment 2) Has declined to participate in this study before the database has been locked

研究者

发起方
Kinki Breast Cancer Study Group

相似试验